Table of Contents
What is agomelatine used for?
Agomelatine is an antidepressant used to treat depression. The brain is usually good at making sure we have enough of the chemicals we need to function properly. But depression can affect a number of brain chemicals.
What class of drug is agomelatine?
Agomelatine is in a unique pharmacological class. Explicitly, unlike other available antidepressants, agomelatine is a melatonin agonist (i.e., MT1 and MT2 receptor-site agonism) and a 5HT2c antagonist. The melatonergic effect is purported to resynchronize circadian rhythms.
What type of drug is Valdoxan?
Valdoxan contains the active ingredient agomelatine. It belongs to a group of medicines called antidepressants. You have been given Valdoxan to treat your depression. Valdoxan is used in adults.
Does agomelatine increase dopamine?
Indeed, agomelatine can increase the extracellular levels of dopamine and NA in the frontal cortex, whereas no change in dopamine level is seen in the nucleus accumbens or the striatum (Millan et al., 2003).
What is the brand name for agomelatine?
Agomelatine is an antidepressant. It is also known by the trade name Valdoxan.
What is the difference between melatonin and agomelatine?
Agomelatine is a synthetic analogue of melatonin. The manufacturers claim that as well as agonising melatonin, it also antagonises the serotonin 5HT2C receptors. Numerous placebo-controlled trials have assessed the efficacy of agomelatine for major depression.
Is agomelatine a melatonin?
Agomelatine is a synthetic agonist of melatonin, a naturally occurring substance, which is secreted by the pineal gland and is involved in the regulation of circadian rhythms and, therefore, sleep patterns.
Is valdoxan a sedative?
At therapeutic doses, in healthy volunteers, VALDOXAN (agomelatine) preserves vigilance and memory, with no sedation in the morning following drug intake.
Is valdoxan safe?
The European Medicines Agency has completed a review of the anti-depressant medicine Valdoxan/Thymanax and concluded that its benefits continue to outweigh the risks. However, the Agency has recommended that further measures should be put in place to minimise the risk of liver toxicity.